

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-17 (cancelled).

18 (currently amended). A method for producing An an antibody to human mannan-binding lectin associated serine protease-2 (MASP-2) comprising produced by administering an antigen comprising a human mannan-binding lectin associated serine protease-2 (human MASP-2) polypeptide to an antibody producing nonhuman animal.

19 (previously presented). An antibody that specifically binds to a human mannan-binding lectin associated serine protease-2 (MASP-2).

20 (currently amended). The antibody of ~~claim 18 or~~ claim 19, wherein said antibody is a monoclonal antibody.

21 (currently amended). The antibody of ~~claim 18 or~~ claim 19, said antibody being coupled to a compound comprising a detectable marker.

22 (currently amended). A pharmaceutical composition comprising the antibody of ~~claims 18 or~~ 19.

23 (previously presented). A method for detecting mannan-binding lectin associated serine protease-2 (MASP-2), said method

(a) obtaining a biological sample;

(b) contacting said biological sample with a MASP-2 polypeptide specific binding partner that specifically binds MASP-2, thereby forming complexes of said binding partner with said MASP-2 polypeptide, if any,; and

(c) detecting said complexes of MASP-2 and said specific MASP-2 binding partner, if any, as an indication of the presence of mannan-binding lectin associated serine protease-2 in said sample,

where said binding partner is an antibody according to claim 19.

24-25 (cancelled).

26 (previously presented). The method of claim 23 for quantitative assay of MASP-2 in biological samples.

27-36 (cancelled).

37 (currently amended). A method for diagnosing a disorder associated with aberrant expression of MASP-2, comprising

obtaining a biological sample from a patient, and measuring MASP-2 expression in said biological sample, wherein increased or decreased MASP-2 expression in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of MASP-2;

correlating MASP-2 expression with presence or absence of said disorder and thereby diagnosing said disorder, where MASP-2 expression is measured by means of an assay reagent comprising an antibody according to ~~claim 18 or~~ claim 19.

38-40 (cancelled).

41 (currently amended). The antibody of ~~claim 18 or~~ claim 19 in which the antibody selectively inhibits the serine protease activity of MASP-2.

42 (cancelled).

43 (currently amended). The antibody of ~~claim 18 or~~ claim 19 in which the antibody inhibits MASP-2 catalyzed cleavage of complement factor C2 or C4.

44 (cancelled).

45 (previously presented). The method of claim 23, further comprising detecting the enzymatic activity of said MASP-2 polypeptide in a sample.